Diabetes 63(10):33943403
The favorable results from the placebo-controlled FLOW trial, conducted with semaglutide 1.0 mg in patients with T2D and chronic kidney disesase (CKD), are about to be disclosed, while ongoing dedicated trials will further explore the effects of OW semaglutide 2.4 mg (NCT04889183) and tirzepatide (NCT05536804) on kidney function parameters in obese/overweight individuals at high risk of CKD progression regardless of T2D
After electron tomography analysis, the IMOD software allows the display of an optical slice cut through the 3D image data in any desired orientation
Which nutrients play a key role in this process
Additionally, while some studies raise concerns about GLP-1s increasing depression, anxiety, and suicidal thoughts, other studies point in the opposite direction, noting a decrease in depressive symptoms, improved cognitive function, and an increase in feelings of self-mastery